What is peptide therapy? What clinics sell, what is legal, and what works

The short answer: peptide therapy is a clinic term for treatment with peptides, the short chains of amino acids that make up hormones such as insulin and GLP-1. The phrase covers three very different things. Some are FDA-approved drugs with large trials, such as tirzepatide and semaglutide. [1] [2] Some are approved drugs used off label, such as tesamorelin. [3] And many are unapproved substances with little or no human evidence, sold as compounded prescriptions or as "research use only" vials.

So the useful question is not "does peptide therapy work?" but "which peptide, for what, and through which channel?" This explainer sorts that out. It does not give doses; for approved drugs the label sets them, and for unapproved peptides there is no established human dose.

What is peptide therapy, and what do clinics mean by it?

When a clinic advertises peptide therapy, it usually means injections, nasal sprays, or creams from a menu of peptides marketed for weight loss, fat loss, recovery, sleep, skin, or "anti-aging." The menu tends to mix categories that the law treats very differently:

• FDA-approved peptide drugs. These have passed clinical trials and carry an FDA label with approved uses, doses, and warnings. Tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and tesamorelin (Egrifta) are examples. [1] [2] [3]
• Compounded peptides. A state-licensed pharmacy mixes the product for an individual patient with a prescription. Under section 503A of the federal drug law, a pharmacy may compound from a bulk ingredient only if it is a component of an approved drug, has a USP monograph, or appears on FDA's 503A bulks list. [4] Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before they are sold. [5]
• Research-only products. Vials labeled "for research use only" or "not for human consumption" are not a lawful prescription product of any kind. FDA has warned that products sold this way may contain the wrong ingredient, the wrong amount, or none at all. [9]

Every peptide on this site carries a regulatory status drawn from FDA and Federal Register sources, and our regulatory tracker logs each change with its date.

Is peptide therapy FDA approved?

Only when the peptide is an approved drug used through a prescription. The rest depends on where each substance sits in FDA's compounding framework. [6]

Approved, with a lawful prescription path today. Among the peptides that clinics sell for body composition, tesamorelin is the clearest case. It is approved as Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy. [3] It cannot be compounded: tesamorelin became a biologic in 2020, and biologics are not eligible for the 503A exemptions. [22] Egrifta WR by prescription is the only lawful product, and use for fat loss in people without HIV is off label.

Awaiting an FDA rule. In April 2026 FDA moved a group of peptides out of Category 2, its list of bulk substances that raise significant safety concerns. [7] On July 23 to 24, 2026, FDA's Pharmacy Compounding Advisory Committee recommended adding six of them to the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon. [8] A committee vote is advisory. None of the six is on the bulks list until FDA publishes a final rule, so a pharmacy has no federal basis to compound them from bulk yet. [6] Our PCAC explainer covers what the vote does and does not change.

No lawful path. CJC-1295, ipamorelin, selank, thymosin alpha-1, injectable GHK-Cu, 5-amino-1MQ, and melanotan II are not approved drugs and are not on the bulks list. [6] Retatrutide, a GLP-1 class drug still in trials, is available lawfully only inside a clinical trial, and FDA has warned about unapproved GLP-1 products sold online, including retatrutide. [9]

A gray zone. Sermorelin was once approved as Geref, which was discontinued. In 2013 FDA determined that Geref was not withdrawn for safety or effectiveness reasons. [14] Many 503A pharmacies compound sermorelin on that basis, and whether that satisfies the law depends on how the pharmacy and its state board read it. Our sermorelin vs tesamorelin comparison lays out the difference.

State law adds another layer: pharmacy licensing, telehealth rules, and board positions vary. Our state legal guides cover all 50 states.

Does peptide therapy work? Evidence by common use

Our evidence grades rank human randomized trials above observational data, and both above animal studies. By the four uses clinics advertise most:

Weight loss. This is where the evidence is strongest, and it belongs to approved GLP-1 drugs. In SURMOUNT-1, tirzepatide 15 mg produced a mean weight change of minus 20.9% at 72 weeks, versus minus 3.1% on placebo. [10] In STEP 1, semaglutide 2.4 mg produced minus 14.9% at 68 weeks, versus minus 2.4%. [11] Retatrutide produced a mean 24.2% loss at 48 weeks at its highest dose in a phase 2 trial, but it is not approved. [12] The obesity condition page grades every option, and our ranking of peptides for weight loss puts them in order.

Growth hormone axis. Tesamorelin has randomized trials, but in a narrow population: in two pooled phase 3 trials of adults with HIV and excess abdominal fat, it reduced visceral fat versus placebo. [13] Those trials do not show that it builds muscle or slows aging in healthy adults. CJC-1295 and ipamorelin, often sold together as a CJC-1295 and ipamorelin blend, have no approved use and no trial of the combination. All of these are prohibited in sport under WADA section S2. [15]

Healing and recovery. BPC-157 and TB-500 have rodent data, not human trials. A 2019 review of BPC-157 concluded that human studies are needed before clinical claims can be made. [16] TB-500 is marketed on the strength of thymosin beta-4 work, which sped wound closure in rats. [17] No trial has tested them together, whatever a "Wolverine stack" label says. See our BPC-157 vs TB-500 comparison and the Wolverine stack page.

Skin. GHK-Cu has laboratory and small cosmetic studies behind topical use. [18] Topical cosmetic products can be sold without FDA approval as long as they make no drug claims. [19] Injectable GHK-Cu is a different matter: it is not an approved drug and not on the 503A bulks list, so it has no lawful path. [6] Blends such as Glow and Klow add injectable ingredients to the mix and inherit that problem. The skin aging condition page grades the options.

Peptide therapy benefits: what is proven and what is not

Claims of better sleep, more energy, sharper memory, or reversed aging are common on clinic menus. For most of the peptides behind them, our records show animal data or small, unreplicated human studies. The proven benefits sit with the approved drugs and their labeled uses: weight reduction and related conditions for the GLP-1 drugs, and abdominal fat reduction in HIV lipodystrophy for tesamorelin. [1] [2] [3] A clinic that promises more than the trials show is selling a hope, not a finding. If you want to check a claim yourself, our guide on how to read a peptide study walks through the questions to ask.

How much does peptide therapy cost?

Prices vary more by channel than by peptide. Branded GLP-1 drugs have published list prices and manufacturer cash programs, compounded peptides are priced by the pharmacy or clinic, and research-labeled products have no lawful price to compare. Our cost index lists dated prices by channel for each peptide, including tesamorelin, where the branded kit is the only lawful option and costs thousands of dollars a month. Clinic membership fees often sit on top of the drug.

Is peptide therapy covered by insurance?

Coverage follows the FDA-approved indication on the prescription. A commercial plan may cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, or tesamorelin for HIV-associated abdominal fat, because those are labeled uses. [1] [3] Standard Medicare Part D plans do not cover drugs prescribed only for weight loss. [20] A separate Medicare GLP-1 Bridge demonstration covers certain GLP-1 drugs for weight management at a 50 USD monthly copay for eligible enrollees from July 1, 2026. [21] Compounded and research-labeled peptides have no approved indication, so there is nothing for a plan to match them to.

Red flags when a clinic offers peptide therapy

Walk away, or at least ask hard questions, when a program:

• Will not say whether a product is an FDA-approved drug, a compounded prescription, or neither. [5]
• Ships vials labeled "research use only" or "not for human consumption." [9]
• Offers a peptide that is not on the 503A bulks list and is not an approved drug, as if it were a routine prescription. [6]
• Sells "stacks" as protocols. No trial has tested the popular combinations, and our peptide stacks explainer explains why that matters.
• Promises athletes a clean test. Most of these peptides are on the WADA list. [15]

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers do offer many peptides that are not approved drugs and are not on the 503A bulks list, and prescribers write prescriptions for them. [6] That does not change their status. Six, including BPC-157, are awaiting an FDA final rule after the July 2026 advisory committee vote, and until then a pharmacy has no federal basis to compound them. [8] Others, such as CJC-1295 and ipamorelin, have no lawful compounding path at all.

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, its Category 2 safety list, and import alerts that let it detain peptide shipments, rather than stopping every pharmacy. [7] [23] [24] [25] [26] State boards of pharmacy oversee pharmacies day to day, and their rules differ. [5]

What changes for you:

• No FDA review of the product. FDA does not verify a compounded drug's safety, effectiveness, or quality before it is sold. [5]
• Identity, purity, sterility, and dose accuracy vary. FDA has cited impurities and immunogenicity risk for several of these peptides. [7]
• Insurance rarely pays, because there is no approved indication to match, so you usually pay cash.
• Sport. Most are prohibited for tested athletes on the WADA list. [15]

What to check: a 503A pharmacy licensed in your state, a real evaluation by a licensed prescriber rather than an online form, and a certificate of analysis for the specific batch. These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Where an approved option exists, it is the lawful route: tesamorelin as Egrifta WR by prescription, [3] and approved GLP-1 drugs such as tirzepatide and semaglutide for weight, collected on the GLP-1 hub.

How to get peptide therapy the lawful way

The lawful route starts with a licensed prescriber, an approved drug or a lawfully compounded one, and a licensed pharmacy. Our companion guide, how to get peptides prescribed, covers which peptides a prescriber can write for today, what telehealth rules apply, and what a legitimate visit looks like. For the GLP-1 class specifically, the GLP-1 hub collects approval status, prices, and state access in one place.